ICAD Focuses On Areas Of High Unmet Need In Cancer Detection, BTIG Says
ICAD Inc (NASDAQ: ICAD) is poised to benefit in the long term from its AI-driven cancer detection tools and electronic brachytherapy product, according to BTIG.
The iCAD Analyst: Marie Thibault initiated coverage of iCAD with a Buy rating and a price target of $25.